According to Hasselberg et al., LMNA mutation carriers were more frequently represented among the 79 non-ischaemic DCM undergoing HT than among the general population of non-ischaemic DCM (6.5% vs. 1.5%, respectively), underscoring the poor prognosis of LMNA-related cardiomyopathies [29]. This evidence concerns the gene LMNA and familial dilated cardiomyopathy.